Canna~Fangled Abstracts

Polysaccharide Cryogels Containing β-Cyclodextrin for the Delivery of Cannabidiol

By October 23, 2021December 30th, 2021No Comments
. 2021 Oct 23;13(11):1774.

doi: 10.3390/pharmaceutics13111774.

Denitsa Momekova 1, Yavor Danov 2, Georgi Momekov 1, Ervin Ivanov 1 3, Petar Petrov 2
Affiliations 

Free PMC article

Abstract

Cannabidiol (CBD) has attracted increasing interest due to its therapeutic potential for treating numerous diseases. However, CBD is very lipophilic and has very unfavorable pharmacokinetics and low bioavailability. Efforts are focused on developing drug delivery systems for enhanced solubilization and therapeutic activity of CBD. Here, we report the preparation of original super-macroporous cryogels from 2-hydroxyethyl cellulose (HEC) and β-cyclodextrin (β-CD) designed for the topical delivery of CBD. The cryogels were synthesized by photochemical crosslinking in a frozen aqueous system, purified, and then loaded with CBD. The effect of HEC/β-CD mass ratio (100:0; 50:50; 40:60 and 20:80) in the reaction mixture on the reaction efficiency, physico-mechanical properties of cryogels, drug release profile, and antineoplastic potential were evaluated in detail. The cryogels showed a bi-phasic release behavior: initial burst release in the first 3 hours followed by slower drug release which can be beneficial in the treatment of cutaneous neoplastic diseases.

Keywords: 2-hydroxyethyl cellulose; cannabidiol; cryogels; drug delivery; β-cyclodextrin.

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Similar articles

See all similar articles

References

    1. Kirilov B., Zhelyazkova M., Petkova-Gueorguieva E., Momekov G. Regulation and marketing of cannabidiol-containing products in European countries. Pharmacists’ knowledge in Bulgaria. Biotechnol. Biotechnol. Equip. 2020;34:1158–1165. doi: 10.1080/13102818.2020.1824620. – DOI
    1. Scuderi C., Filippis D.D., Iuvone T., Blasio A., Steardo A., Esposito G. Cannabidiol in medicine: A review of its therapeutic potential in CNS disorders. Phytother. Res. 2009;23:597–602. doi: 10.1002/ptr.2625. – DOI – PubMed
    1. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg. Med. Chem. 2015;23:1377–1385. doi: 10.1016/j.bmc.2015.01.059. – DOI – PubMed
    1. Millar S.A., Stone N.L., Yates A.S., O’Sullivan S.E. A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol. 2018;9:1365. doi: 10.3389/fphar.2018.01365. – DOI – PMC – PubMed
    1. Noreen N., Muhammad F., Akhtar B., Azam F., Anwar M.I. Is cannabidiol a promising substance for new drug development? A review of its potential therapeutic applications. Crit. Rev. Eukaryot. Gene Expr. 2018;28:73–86. doi: 10.1615/CritRevEukaryotGeneExpr.2018021528. – DOI – PubMed

Leave a Reply